

Vicriviroc (maleate)

Catalog No: tcsc1019



Available Sizes

Size: 5mg



Specifications

CAS No:

599179-03-0

Formula:

$C_{32}H_{42}F_3N_5O_6$

Pathway:

Immunology/Inflammation;GPCR/G Protein;Anti-infection

Target:

CCR;CCR;HIV

Purity / Grade:

>98%

Solubility:

H₂O : 25 mg/mL (38.48 mM; Need ultrasonic and warming); DMSO : 50 mg/mL (76.96 mM; Need ultrasonic)

Alternative Names:

SCH-417690 (maleate);SCH-D (maleate)

Observed Molecular Weight:

649.7

Product Description


Vicriviroc maleate is a potent, selective, oral bioavailable and CNS penetrated antagonist of **CCR5**, with a **K_i** of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with **IC₉₀**s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU 570).

IC₅₀ & Target: Ki: 2.5 nM (CCR5)^[1]

IC₉₀: 3.3 nM (HIV-1 JrFL, in PBMC cells), 2.8 nM (HIV-1 ADA-M, in PBMC cells), 1.8 nM (HIV-1 301657, in PBMC cells), 4.9 nM (HIV-1 JV1083, in PBMC cells) and 10 nM (HIV-1 RU 570, in PBMC cells)^[1]

In Vitro: Vicriviroc (Sch-417690/Sch-D) is a potent, selective and oral bioavailable inhibitor of CCR5, with a K_i of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC₉₀s of 3.3 (JrFL), 2.8 (ADA-M), 1.8 (301657), 4.9 (JV1083) and 10 nM (RU 570). In addition, Vicriviroc shows a mean IC₅₀ and IC₉₀ of 0.45 nM and 4 nM for a panel of HIV isolates, and has weak activity against hERG activity (IC₅₀, 5.8 μM)^[1]. Vicriviroc inhibits chemotactic response to MIP-1α with IC₅₀ values below 1 nM, and suppresses RANTES-induced signaling with a mean IC₅₀ of 4.2 ± 1.3 nM. Vicriviroc potently suppresses all the viral isolates tested, with geometric mean EC₅₀s of 0.04-2.3 nM and IC₉₀s of 0.45-18 nM^[2].

In Vivo: Vicriviroc (10 mg/kg) has good oral availability in rats and monkeys, with no acute CNS or GI effects in rats^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!